$CLCS
Cell Source, Inc. Stock $clcs

$clcs Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223040079 Filed on November 09, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$507.0K	$480.0K	$540.0K
YoY Change	-16.56%	-10.03%	16.29%
% of Gross Profit
Research & Development	$359.4K	$510.0K	$370.0K
YoY Change	-22.73%	8.97%	-33.33%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$866.4K	$995.4K	$905.5K
YoY Change	-19.24%	-2.03%	-12.42%
Operating Profit		-$995.4K	-$905.5K
YoY Change		-2.03%	-12.42%
Interest Expense	-$40.95K	-$340.0K	-$380.0K
YoY Change	-84.52%	43.91%	-700.19%
% of Operating Profit
Other Income/Expense, Net		-$342.8K	-$336.1K
YoY Change		45.07%	33.54%
Pretax Income	-$1.050M	-$1.340M	-$1.240M
YoY Change	-21.49%	7.0%	-3.55%
Income Tax
% Of Pretax Income
Net Earnings	-$1.371M	-$1.338M	-$1.242M
YoY Change	-15.63%	6.85%	-3.42%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.04	-$0.04
Diluted Earnings Per Share	-$0.04	-$0.04	-$0.04
COMMON SHARES
Basic Shares Outstanding	38.55M shares	38.16M shares	37.21M shares
Diluted Shares Outstanding		38.19M shares	37.21M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.20K	$0.00	$20.00K
YoY Change	-90.03%	-100.0%	669.23%
Cash & Equivalents	$22.20K	$2.582K	$21.99K
Short-Term Investments
Other Short-Term Assets	$12.22K	$3.400K	$16.34K
YoY Change	-46.89%	-83.29%	1.26%
Inventory
Prepaid Expenses	$160.8K	$242.4K	$324.0K
Receivables
Other Receivables
Total Short-Term Assets	$195.2K	$250.0K	$360.0K
YoY Change	-52.38%	-30.67%	706.45%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.00	-$1.643K	$2.329K
YoY Change	-120.0%	-164400.0%
TOTAL ASSETS
Total Short-Term Assets	$195.2K	$250.0K	$360.0K
Total Long-Term Assets	$1.00	-$1.643K	$2.329K
Total Assets	$195.2K	$248.4K	$362.3K
YoY Change	-52.38%	-31.13%	711.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.467M	$1.581M	$927.8K
YoY Change	115.64%	134.47%	142.87%
Accrued Expenses	$4.750M	$4.550M	$4.370M
YoY Change	219.68%	254.19%	191.15%
Deferred Revenue
YoY Change
Short-Term Debt	$710.3K	$680.0K	$680.0K
YoY Change	-7.53%	-10.54%	-9.39%
Long-Term Debt Due	$1.229M	$1.480M	$1.800M
YoY Change	16.11%	72.46%	123.12%
Total Short-Term Liabilities	$15.81M	$16.28M	$15.31M
YoY Change	21.18%	32.2%	41.61%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.81M	$16.28M	$15.31M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$15.81M	$16.28M	$15.31M
YoY Change	21.18%	32.19%	41.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$41.67M	-$40.62M	-$39.28M
YoY Change	14.64%	16.02%	16.36%
Common Stock	$39.83K	$38.50K	$38.16K
YoY Change	10.39%	9.22%	8.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$15.61M	-$16.03M	-$14.95M
YoY Change
Total Liabilities & Shareholders Equity	$195.2K	$248.4K	$362.3K
YoY Change	-52.38%	-31.13%	711.67%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$1.371M	-$1.338M	-$1.242M
YoY Change	-15.63%	6.85%	-3.42%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$717.9K	-$280.0K	-$1.040M
YoY Change	-0.75%	-74.23%	246.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	737.4K	270.0K	920.0K
YoY Change	-16.2%	-76.52%	437.41%
NET CHANGE
Cash From Operating Activities	-717.9K	-280.0K	-1.040M
Cash From Investing Activities
Cash From Financing Activities	737.4K	270.0K	920.0K
Net Change In Cash	19.54K	-10.00K	-120.0K
YoY Change	-87.53%	-115.79%	-7.26%
FREE CASH FLOW
Cash From Operating Activities	-$717.9K	-$280.0K	-$1.040M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001569340
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	CLCS	Financing Of Directors And Officers Insurance FinancingOfDirectorsAndOfficersInsurance		usd
	CLCS	Conversion Of Series C Convertible Preferred Stock Into Common Stock ConversionOfSeriesCConvertiblePreferredStockIntoCommonStock		usd
	CLCS	Conversion Of Accrued Expenses Into Note Principal ConversionOfAccruedExpensesIntoNotePrincipal		usd
	CLCS	Warrants Issued In Satisfaction Of Accrued Warrant Obligation WarrantsIssuedInSatisfactionOfAccruedWarrantObligation		usd
	CLCS	Issuance Of Warrants In Satisfaction Of Accrued Interest IssuanceOfWarrantsInSatisfactionOfAccruedInterest		usd
	CLCS	Extinguishment Of Note Payable For Common Stock ExtinguishmentOfNotePayableForCommonStock		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-55413
	dei	Entity Registrant Name EntityRegistrantName	Cell Source, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	32-0379665
	dei	Entity Address Address Line1 EntityAddressAddressLine1	57 West 57th Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10019
	dei	City Area Code CityAreaCode	(646)
	dei	Local Phone Number LocalPhoneNumber	416-7896
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38546231	shares
CY2023Q3	us-gaap	Cash Cash	2582	usd
CY2022Q4	us-gaap	Cash Cash	222665	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	242375	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	164175	usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	3400	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	23005	usd
CY2023Q3	us-gaap	Assets Assets	248357	usd
CY2022Q4	us-gaap	Assets Assets	409845	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1580863	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	680325	usd
CY2023Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	885665	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	849898	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	130040	usd
CY2023Q3	us-gaap	Dividends Payable Current DividendsPayableCurrent	310630	usd
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	5217	usd
CY2023Q3	us-gaap	Liabilities Liabilities	16278504	usd
CY2022Q4	us-gaap	Liabilities Liabilities	13043740	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38495617	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38495617	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36081758	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36081758	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	38495	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	36082	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24546969	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23674354	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40617485	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36346176	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-16030147	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-12633895	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	248357	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	409845	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	480875	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	533538	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2097801	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1571572	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	995380	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	1016043	usd
	us-gaap	Operating Expenses OperatingExpenses	3316394	usd
	us-gaap	Operating Expenses OperatingExpenses	3102592	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-995380	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1016043	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3316394	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3102592	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	41920	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-342758	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-236263	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-954915	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-727883	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1338138	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1252306	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4271309	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3830475	usd
CY2023Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	309150	usd
CY2022Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	299827	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	907516	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	869715	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1647288	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1552133	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5178825	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4700190	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38191731	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38191731	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35240745	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35240745	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37492478	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37492478	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34696011	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34696011	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-12633895	usd
CY2023Q1	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Convertible Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock	52060	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-297517	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	21202	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	330000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1691567	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-14219717	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-300849	usd
CY2023Q2	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	602102	usd
CY2023Q2	CLCS	Stock Issued During Issuance Of Common Stock In Connection With Extinguishment Of Note Payable StockIssuedDuringIssuanceOfCommonStockInConnectionWithExtinguishmentOfNotePayable	58080	usd
CY2023Q2	CLCS	Warrants Issued In Satisfaction Of Accrued Interest WarrantsIssuedInSatisfactionOfAccruedInterest	40167	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	75462	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	40600	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1241604	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-14945759	usd
CY2023Q3	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Convertible Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock	494134	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	45008	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-309150	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	23758	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1338138	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-16030147	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9826135	usd
CY2022Q1	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Convertible Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock	1433095	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-324917	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	8043	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	5372	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1292575	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-9997117	usd
CY2022Q2	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Convertible Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock	114473	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-244971	usd
CY2022Q2	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	597431	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	49219	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1285594	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-10766559	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-10766559	usd
CY2022Q3	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Convertible Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock	98886	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-299827	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	76509	usd
CY2022Q3	CLCS	Warrants Issued In Satisfaction Of Accrued Interest WarrantsIssuedInSatisfactionOfAccruedInterest	114727	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	74600	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1252306	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-11953970	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-11953970	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4271309	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3830475	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	41920	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	361692	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	187802	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-28695	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-96896	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-243300	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	70568	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-19605	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	3431	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	900538	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	451179	usd
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	25147	usd
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	63846	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1625601	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2415411	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	168094	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	146912	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	191460	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27926	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1405518	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2388256	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-220083	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-27155	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	222665	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	93095	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2582	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	65940	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	949	usd
	CLCS	Accrual Of Earned Preferred Stock Dividends AccrualOfEarnedPreferredStockDividends	-907516	usd
	CLCS	Accrual Of Earned Preferred Stock Dividends AccrualOfEarnedPreferredStockDividends	-869715	usd
	us-gaap	Stock Issued1 StockIssued1	602102	usd
	us-gaap	Stock Issued1 StockIssued1	597431	usd
	CLCS	Financing Of Directors And Officers Insurance FinancingOfDirectorsAndOfficersInsurance	321500	usd
	CLCS	Conversion Of Series C Convertible Preferred Stock Into Common Stock ConversionOfSeriesCConvertiblePreferredStockIntoCommonStock	400	usd
	CLCS	Conversion Of Accrued Expenses Into Note Principal ConversionOfAccruedExpensesIntoNotePrincipal	413018	usd
	CLCS	Accrual Of Warrant Obligations In Connection With Issuance Of Notes Payable AccrualOfWarrantObligationsInConnectionWithIssuanceOfNotesPayable	40167	usd
	CLCS	Accrual Of Warrant Obligations In Connection With Issuance Of Notes Payable AccrualOfWarrantObligationsInConnectionWithIssuanceOfNotesPayable	232697	usd
	CLCS	Warrants Issued In Satisfaction Of Accrued Warrant Obligation WarrantsIssuedInSatisfactionOfAccruedWarrantObligation	-40167	usd
	CLCS	Issuance Of Warrants In Connection With Issuance Of Notes Payable IssuanceOfWarrantsInConnectionWithIssuanceOfNotesPayable	141672	usd
	CLCS	Issuance Of Warrants In Connection With Issuance Of Notes Payable IssuanceOfWarrantsInConnectionWithIssuanceOfNotesPayable	133771	usd
	CLCS	Issuance Of Warrants In Satisfaction Of Accrued Interest IssuanceOfWarrantsInSatisfactionOfAccruedInterest	114727	usd
	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCPreferredStockAndCommonStock	546194	usd
	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCPreferredStockAndCommonStock	1646454	usd
	CLCS	Extinguishment Of Note Payable For Common Stock ExtinguishmentOfNotePayableForCommonStock	58080	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4271000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1626000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-16030000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40617000	usd
	CLCS	Share Based Compensation Included In Stockholders Deficiency ShareBasedCompensationIncludedInStockholdersDeficiency	79972	usd
	CLCS	Accrued Compensation AccruedCompensation	182	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	52709434	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	39915479	shares
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	563920	usd
CY2023Q1	CLCS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accrual Of Warrant Obligation FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfWarrantObligation	40167	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-47226	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	556861	usd
CY2023Q2	CLCS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accrual Of Common Stock Obligation FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfCommonStockObligation	9438	usd
CY2023Q2	CLCS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Warrant Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisWarrantIssues	-40167	usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	27345	usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	553477	usd
CY2023Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	49758	usd
CY2023Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	603235	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	463650	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	33197	usd
CY2022Q1	CLCS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accrual Of Warrant Obligation FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfWarrantObligation	114727	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	611574	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	29732	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	641306	usd
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	33786	usd
CY2022Q3	CLCS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accrual Of Warrant Obligation FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfWarrantObligation	58985	usd
CY2022Q3	CLCS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Warrant Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisWarrantIssues	-114727	usd
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	619350	usd
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	183095	shares
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	154495	shares
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	62252	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	50983	usd
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.34
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.33
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	one vote per share
CY2023Q3	CLCS	Share Based Compensation Included In Stockholders Deficiency ShareBasedCompensationIncludedInStockholdersDeficiency	23758	usd
CY2023Q3	CLCS	Accrued Compensation AccruedCompensation	372	usd
CY2022Q3	CLCS	Share Based Compensation Included In Stockholders Deficiency ShareBasedCompensationIncludedInStockholdersDeficiency	74600	usd
CY2022Q3	CLCS	Accrued Compensation AccruedCompensation	156	usd
	CLCS	Share Based Compensation Included In Stockholders Deficiency ShareBasedCompensationIncludedInStockholdersDeficiency	64358	usd
	CLCS	Accrued Compensation AccruedCompensation	649	usd
CY2019Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	267680	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	146912	usd
CY2023Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	38838	usd
CY2023Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	106000	usd
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	360000	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-040079-index-headers.html	Edgar Link	pending
0001493152-23-040079-index.html	Edgar Link	pending
0001493152-23-040079.txt	Edgar Link	pending
0001493152-23-040079-xbrl.zip	Edgar Link	pending
clcs-20230930.xsd	Edgar Link	pending
ex-31.htm	Edgar Link	pending
ex-32.htm	Edgar Link	pending
ex10-39c.htm	Edgar Link	pending
ex10-39c_001.jpg	Edgar Link	pending
ex10-39c_002.jpg	Edgar Link	pending
clcs-20230930_cal.xml	Edgar Link	unprocessable
clcs-20230930_def.xml	Edgar Link	unprocessable
clcs-20230930_lab.xml	Edgar Link	unprocessable
clcs-20230930_pre.xml	Edgar Link	unprocessable
ex10-39c_003.jpg	Edgar Link	pending
ex10-39c_004.jpg	Edgar Link	pending
ex10-39c_005.jpg	Edgar Link	pending
ex10-39d.htm	Edgar Link	pending
ex10-39d_001.jpg	Edgar Link	pending
ex10-39d_002.jpg	Edgar Link	pending
ex10-39d_003.jpg	Edgar Link	pending
ex10-39d_004.jpg	Edgar Link	pending
ex10-39d_005.jpg	Edgar Link	pending
ex10-39d_006.jpg	Edgar Link	pending
ex10-64d.htm	Edgar Link	pending
ex10-64d_001.jpg	Edgar Link	pending
ex10-68b.htm	Edgar Link	pending
ex10-68b_001.jpg	Edgar Link	pending
ex10-68b_002.jpg	Edgar Link	pending
ex3-6.htm	Edgar Link	pending
ex3-6_001.jpg	Edgar Link	pending
ex3-6_002.jpg	Edgar Link	pending
ex3-6_003.jpg	Edgar Link	pending
ex3-6_004.jpg	Edgar Link	pending
ex3-6_005.jpg	Edgar Link	pending
ex3-6_006.jpg	Edgar Link	pending
ex3-6_007.jpg	Edgar Link	pending
ex3-6_008.jpg	Edgar Link	pending
ex3-6_009.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLCS
Cell Source, Inc. Stock $clcs

2023 Q4 Form 10-Q Financial Statement

#000149315223040079 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLCS Cell Source, Inc. Stock $clcs

2023 Q4 Form 10-Q Financial Statement

#000149315223040079 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLCS
Cell Source, Inc. Stock $clcs